Want to see RVP full AI Analyst Report?
Top Page
Retractable Technologies
(RVP)
Select Model
Select Model
Rating:47Neutral
Price Target:
$0.57
▼(-22.33% Downside)
Action:Reiterated
Date:10/01/26
The score is held down primarily by weak operating performance and cash burn alongside continuing losses, despite a balance-sheet advantage from very low leverage. Technical indicators are largely neutral with only mild downside bias, providing limited support. Valuation is constrained by negative earnings (negative P/E) and no provided dividend yield for the common stock; a preferred-share dividend declaration is a small positive but not enough to offset the fundamental headwinds.
Positive Factors
Low Leverage
Very low leverage reduces refinancing exposure and preserves financial flexibility while the company works through operating weakness. A sizable equity base relative to assets also provides a cushion against volatility and leaves more capacity to fund operations without relying heavily on additional debt.
Negative Factors
Revenue Contraction
Declining revenue signals weaker recent demand or sales execution and reduces the scale available to absorb fixed operating costs. Unless the company restores top-line growth, the contraction can prolong losses, limit investment capacity, and make sustained margin improvement more difficult.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Very low leverage reduces refinancing exposure and preserves financial flexibility while the company works through operating weakness. A sizable equity base relative to assets also provides a cushion against volatility and leaves more capacity to fund operations without relying heavily on additional debt.
Read all positive factors
Retractable Technologies (RVP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$17.25M
Dividend YieldN/A
Average Volume (3M)32.42K
Price to Earnings (P/E)―
Beta (1Y)0.51
Revenue Growth-11.16%
EPS Growth59.85%
CountryUS
Employees198
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.12
Shares Outstanding29,937,159
10 Day Avg. Volume26,147
30 Day Avg. Volume32,425
Financial Highlights & Ratios
PEG Ratio-0.24
Price to Book (P/B)0.31
Price to Sales (P/S)0.60
P/FCF Ratio-3.04
Enterprise Value/Market Cap-1.00
Enterprise Value/Revenue-0.51
Enterprise Value/Gross Profit-46.45
Enterprise Value/Ebitda-3.81
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Retractable Technologies Business Overview & Revenue Model
Company Description
Retractable Technologies, Inc. is a medical device company focused on the innovation, production, and sale of secure medical instruments, predominantly syringes, for the healthcare sector. Their reach extends across the United States, the broader ...
Retractable Technologies Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
72
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 33.90M | 38.27M | 33.05M | 43.60M | 94.82M | 188.38M |
| Gross Profit | 371.53K | 47.05K | -1.03M | 9.11M | 28.25M | 95.35M |
| EBITDA | 4.53M | -4.42M | 4.17M | -1.24M | 9.94M | 76.44M |
| Net Income | -3.37M | -12.57M | -11.89M | -7.01M | 5.08M | 56.06M |
Balance Sheet | ||||||
| Total Assets | 141.69M | 142.63M | 160.72M | 179.67M | 210.74M | 213.15M |
| Cash, Cash Equivalents and Short-Term Investments | 39.87M | 36.97M | 44.56M | 47.29M | 49.38M | 42.43M |
| Total Debt | 715.92K | 895.64K | 1.23M | 1.54M | 2.92M | 4.24M |
| Total Liabilities | 68.83M | 68.26M | 73.55M | 80.38M | 104.21M | 113.98M |
| Stockholders Equity | 72.87M | 74.38M | 87.17M | 99.29M | 106.54M | 99.17M |
Cash Flow | ||||||
| Free Cash Flow | -5.11M | -7.60M | -13.00M | 1.91M | -61.95K | -25.57M |
| Operating Cash Flow | -4.96M | -7.06M | -11.56M | 2.77M | 16.77M | 32.79M |
| Investing Cash Flow | 5.18M | 5.98M | 3.66M | -10.76M | -31.20M | -63.04M |
| Financing Cash Flow | -632.04K | -567.32K | -535.43K | 941.64K | 4.99M | 41.84M |
Retractable Technologies Technical Analysis
Negative
0.73
Price Trends
0.67
Negative
0.68
Negative
0.68
Negative
Market Momentum
-0.03
Positive
25.32
Positive
33.49
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RVP, the sentiment is Negative. The current price of 0.73 is above the 20-day moving average (MA) of 0.62, above the 50-day MA of 0.67, and above the 200-day MA of 0.68, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 25.32 is Positive, neither overbought nor oversold. The STOCH value of 33.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RVP.
Retractable Technologies Risk Analysis
Retractable Technologies disclosed 18 risk factors in its most recent earnings report. Retractable Technologies reported the most risks in the "Macro & Political" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Retractable Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $281.39M | -5.91 | -14.73% | ― | -18.86% | -0.63% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $28.55M | -6.60 | -149.08% | ― | 3.72% | 43.78% | |
47 Neutral | $17.25M | -4.79 | -4.59% | ― | -11.16% | 59.85% | |
45 Neutral | $302.42M | -8.85 | -473.55% | 0.00% | 12.93% | -219.19% | |
44 Neutral | $91.18M | -3.68 | -132.62% | ― | -5.47% | 13.55% |
* Healthcare Sector Average
RVP
Retractable Technologies
0.58
-0.30
-34.32%
OSUR
Orasure Technologies
4.08
1.34
48.91%
STXS
Stereotaxis
0.91
-2.00
-68.73%
MLSS
Milestone Scientific
0.32
-0.10
-24.82%
SMTI
Sanara MedTech
32.92
3.61
12.34%
Retractable Technologies Corporate Events
Business Operations and StrategyDividends
Retractable Technologies Declares Dividend on Preferred Shares
Positive
Sep 30, 2026
On September 30, 2026, Retractable Technologies announced it had declared a dividend for holders of its Series II and Series III Class B Convertible Preferred Stock. The move highlights the company’s capital allocation to preferred sharehold...
Financial DisclosuresRegulatory Filings and Compliance
Retractable Technologies Reports Latest Quarterly Financial Results
Neutral
Aug 14, 2026
On August 14, 2026, Retractable Technologies announced its financial results for the periods ended June 30, 2026. The release of these results provides stakeholders with updated visibility into the company’s recent operating performance and ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.